Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). - Test2 - elhamkhani - TriplyDB

Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).

Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).

http://www.wikidata.org/entity/Q35052199

about

Interferon-β-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab Fingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidence What do we know about brain contrast enhancement patterns in neuromyelitis optica?Ultrahigh field MRI in clinical neuroimmunology: a potential contribution to improved diagnostics and personalised disease management Hypoxemia, Sleep Disturbances, and Depression Correlated with Fatigue in Neuromyelitis Optica Spectrum Disorder.Restoring immune tolerance in neuromyelitis optica: Part II Treatment of neuromyelitis optica: state-of-the-art and emerging therapies Treatment of primary Sjögren syndrome.[Tryptophan immunoadsorption for multiple sclerosis and neuromyelitis optica: therapy option for acute relapses during pregnancy and breastfeeding].MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome Neuromyelitis optica: clinical features, immunopathogenesis and treatment.[Contribution of spinal cord biopsy to the differential diagnosis of longitudinal extensive transverse myelitis].Longitudinally extensive transverse myelitis in neuromyelitis optica: a prospective study of 13 Caucasian patients and literature review.The Diagnosis and Treatment of Optic Neuritis Fatigue in patients with neuromyelitis optica spectrum disorder and its impact on quality of life.Systemic Lupus Erythematosus (SLE) Complicated by Neuromyelitis Optica (NMO - Devic's Disease): Clinic-Pathological Report and Review of the Literature.Aquaporin-4 antibody testing: direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate.Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders.Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research.Late-onset neuromyelitis optica spectrum disorder in AQP4-seropositivepatients in a Chinese population.The Urine Proteome Profile Is Different in Neuromyelitis Optica Compared to Multiple Sclerosis: A Clinical Proteome Study Next-generation sequencing identifies altered whole blood microRNAs in neuromyelitis optica spectrum disorder which may permit discrimination from multiple sclerosis.The intrathecal, polyspecific antiviral immune response in neurosarcoidosis, acute disseminated encephalomyelitis and autoimmune encephalitis compared to multiple sclerosis in a tertiary hospital cohort.The role of anti-aquaporin 4 antibody in the conversion of acute brainstem syndrome to neuromyelitis optica.A Case Study of Intractable Vomiting with Final Diagnosis of Neuromyelitis Optica A diagnostic challenge in a young woman with intractable hiccups and vomiting: a case of neuromyelitis optica Efficacy and safety of rituximab in neuromyelitis optica: Review of evidence.Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity.Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis.A Urinary Metabolic Signature for Multiple Sclerosis and Neuromyelitis Optica High avidity chimeric monoclonal antibodies against the extracellular domains of human aquaporin-4 competing with the neuromyelitis optica autoantibody, NMO-IgG.Placebo-controlled study in neuromyelitis optica-Ethical and design considerations Immunoadsorption in patients with neuromyelitis optica spectrum disorder.Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder.MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients.MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.Development of a patient-centred conceptual framework of health-related quality of life in neuromyelitis optica: a qualitative study.Recent advances in the neuroimmunology of cell-surface CNS autoantibody syndromes, Alzheimer's disease, traumatic brain injury and schizophrenia.

P2860

Q21146701-EBDDFB57-5060-4951-A9B8-A4AE85C58176 Q26752466-E86B1DA0-5CE7-495E-8587-940DF206E5D5 Q26776278-E91242F9-E8A3-4821-AD7E-6FAF57D707B4 Q26796643-1B3D118C-CF24-480F-AA3C-4D38239D2201 Q27313852-1C8FA8C1-C9A0-4454-8094-E83339B50619 Q28070136-BB677AA9-CBC0-4A57-B1D6-DBE5916CC3FF Q28245749-52C30199-076A-4E72-96F3-77B36D011D20 Q30249011-3C3E8A41-8CB7-4D8F-B48F-6A6762EBE95D Q30316840-7B2D18D1-B587-4AC1-9699-86217041D0AC Q30371412-A46D1694-307D-45B2-BC43-FB06BA9902ED Q30785267-719AEEA4-8227-4B24-917F-3EA94BAC1C93 Q30844319-4F34045E-DD7C-46B2-BFB6-9AA9A97C1F9C Q30945169-9D4459AA-8BF3-48F8-9B57-896FEDDFBF75 Q30995944-46F22E60-95DD-46E7-BEF6-166678312772 Q33719007-F918D972-2BA7-44AC-B8CD-00CE424D7E45 Q33734731-3F77181E-2C9F-45AB-9C8D-53E79F72A7D2 Q34026880-F6F2BE8C-1C79-4B7B-9612-F163C659A424 Q34545836-2C56FB71-EC7D-4133-8176-D92F2FF5C357 Q35228937-FB65E4AA-81DF-4DCC-9976-B10F7F902321 Q35763927-3B244541-BCD3-4EDD-9A4B-2C975AFD7101 Q35804573-EC400769-8043-448D-BBC3-4A0E2350CE42 Q35828632-A1E5B76C-BCFD-4800-B41E-D4AE282F3013 Q35864847-5EE131D1-34C0-44F2-90C4-D0C204B47BA7 Q36171516-1D5A9F23-D0C4-4C19-B511-895E9357FD8B Q36174210-F0348255-C1C0-45EF-BBC0-8802567A73D7 Q36181695-D476EF6D-E1CA-4A44-9579-CC0CBE48F097 Q36359371-E924C817-7B82-4801-AD13-5EADB466E5AE Q36484394-EECCD448-631B-48A4-9AD4-452BB92E443B Q36484399-BA1A54D4-24D4-4955-B107-724F708E2DB2 Q36490876-848155F7-5DD9-4AC6-A403-15CC0AE24187 Q36562604-1A4AB623-87BB-48F7-B826-D76A5602B0A9 Q36635131-6779DEF0-2AE1-4FC9-8430-24635B4E578F Q36744223-55B46037-0DFB-4E86-A24C-50C59FEA2600 Q36996492-55AC2B19-26E6-4F02-8E53-63600ED807CE Q37027700-126EEEE9-E690-476A-B960-3F96728214EF Q37365089-4A4259CA-E317-40C2-9776-FCA5D6D4491A Q37383474-06FE47A6-B3FA-48A8-A46F-96D89EA26C01 Q37383555-97C80C3E-70BE-4CE3-9954-B87856B2C057 Q37567603-F46FADE3-60F3-474F-AEE0-0E90A5F41EDC Q38245624-3037C3B0-1D71-4EF2-A8AB-48AD90278507

P2860

Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).

http://www.wikidata.org/entity/Q35052199

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Update on the diagnosis and tr ...... is Optica Study Group (NEMOS).

@ast

Update on the diagnosis and tr ...... is Optica Study Group (NEMOS).

@en

type

label

Update on the diagnosis and tr ...... is Optica Study Group (NEMOS).

@ast

Update on the diagnosis and tr ...... is Optica Study Group (NEMOS).

@en

prefLabel

Update on the diagnosis and tr ...... is Optica Study Group (NEMOS).

@ast

Update on the diagnosis and tr ...... is Optica Study Group (NEMOS).

@en

P1433

Q35052199-353EF6CD-6CF9-4093-ADBC-5AE06B97930B

P1476

Q35052199-7B7E0C83-C2E3-43CC-B217-6A0BE60FD296

P2093

Q35052199-00FA70A0-3C62-47BA-AAFD-2C340A13C591

Q35052199-17A928AC-6FD0-4E70-BC07-495D12DE1E57

Q35052199-3EE4999A-FAA6-4811-9002-0F86B8618A97

Q35052199-415BD999-C272-445D-97CA-50B5694E6765

Q35052199-72F45974-6629-4AAA-A751-A0866C60177D

Q35052199-9B0B4E4E-92FC-4211-9CC2-97C9B7519767

Q35052199-AE5A1AC7-AF3A-4D5D-8F4D-DD829E4579F9

Q35052199-E03845C6-B656-4795-8D2B-ACBC3096DCB0

Q35052199-EF37A3FC-C42C-4A80-B79B-6C231911685C

P2860

Q35052199-019FD199-FDC0-4467-8161-740F5EAB86C9

Q35052199-030181B8-C1E9-4C69-9F49-0E7FD1A424A8

Q35052199-040268AE-24EF-498C-A94C-2DD8ED9B60FE

Q35052199-05B6C463-BE89-44E8-987C-B69653F76FAD

Q35052199-0873C637-3C59-4973-B0D3-87936BD4D80B

Q35052199-09CB9DAB-03C6-407C-93C3-36FBD91BCD3B

Q35052199-0A448191-771A-44C9-9245-7C214369AD43

Q35052199-0A854283-60EC-461F-8245-B4164945016D

Q35052199-0F084D97-EBF0-4683-9FF2-E1821F6AE7E7

Q35052199-0F08E2FC-C542-4757-85B6-8B9EE06A125D

P2888

Q35052199-842EF436-23E5-4C93-9F74-2942B95AF826

P304

Q35052199-A9D40E10-5758-40FE-99D0-40FC58C015DC

P31

Q35052199-A9A44554-8207-42E5-BE93-F0264258C7F4

Q35052199-C0050F72-8CC1-4A52-9E52-90BEE5F7DF52

P356

Q35052199-0710CFD3-EE01-49F5-8B97-00EAA73B1F94

P433

Q35052199-EBCE4888-A4C6-4483-A1A9-D100988DA23F

P478

Q35052199-1F6985C6-B840-47A6-86DA-939E483F20EF

P50

Q35052199-A33046E5-5907-4BFA-9EC6-97D64914BB5A

Q35052199-B86EE3DC-030D-4727-A824-ED1FE51ECEB5

P577

Q35052199-4D31E30E-E66E-49E8-975D-6FD6D4E59D5F

Q35052199-4D50E93B-B1E6-4EA2-B591-9395CE953792

P5875

Q35052199-49D2BC6E-66D7-4D8D-8213-6143E3081E43

P698

Q35052199-F8327305-542D-45EC-BF7A-2DAF7D1CE128

P921

Q35052199-18D95807-1B01-45DE-913B-24AF1580BED9

P932

Q35052199-E08DC137-7E0A-42B9-BC7A-29C4291680B4

P356

S00415-013-7169-7

P1433

Journal of Neurology

P1476

Update on the diagnosis and tr ...... is Optica Study Group (NEMOS).

@en

P2093

Achim Berthele

http://www.w3.org/2001/XMLSchema#string

Brigitte Wildemann

http://www.w3.org/2001/XMLSchema#string

Corinna Trebst

http://www.w3.org/2001/XMLSchema#string

Ingo Kleiter

http://www.w3.org/2001/XMLSchema#string

Nadja Borisow

http://www.w3.org/2001/XMLSchema#string

Neuromyelitis Optica Study Group (NEMOS)

http://www.w3.org/2001/XMLSchema#string

Orhan Aktas

http://www.w3.org/2001/XMLSchema#string

Sven Jarius

http://www.w3.org/2001/XMLSchema#string

Sven Schippling

http://www.w3.org/2001/XMLSchema#string

P2860

Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients

Comparative brain stem lesions on MRI of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis

Association of retinal and macular damage with brain atrophy in multiple sclerosis

Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica

Neuromyelitis optica pathogenesis and aquaporin 4

The history of neuromyelitis optica

Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab

Aquaporin 4 and neuromyelitis optica

IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel

Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis

P2888

s00415-013-7169-7

P304

1-16

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00415-013-7169-7

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

261

http://www.w3.org/2001/XMLSchema#string

P50

Friedemann Paul

P577

2013-11-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260944442

http://www.w3.org/2001/XMLSchema#string

P698

24272588

http://www.w3.org/2001/XMLSchema#string

P921

neuromyelitis optica

P932

3895189

http://www.w3.org/2001/XMLSchema#string